

**PATENT COOPERATIVE TREATY**  
**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE**

Application of: DONG et al.

Serial No.: (not yet assigned)

Art Unit: (not yet assigned)

Filed: (concurrently herewith)

Entitled: GHRELIN ANALOGS

Examiner: (not yet assigned)

**U.S. national phase of Int'l Appln. PCT/US03/022925 filed July 23, 2003, designating the U.S.**  
Atty. Docket No.: BIO-113P/PCT3/US (BIO-113.2P US)

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**Statement of Sequence Listing Paper Copy and**  
**Computer-Readable Form Identity Under 37 CFR §§1.821-1.825**

Sir:

Transmitted herewith please find: a diskette containing a computer readable form (CRF) of a Sequence Listing, and a paper copy of the Sequence Listing filed currently with this paper as required under 37 CFR §1.821(e);

Applicants have assigned a separate identifier to each of the 5 sequences disclosed, as required by 37 CFR §§1.821-1.825.


Applicants verify the following:

1. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are the same in content, as required by 37 CFR §1.825(b);
2. The enclosed Sequence Listing for the above-identified patent application contains no new matter and does not go beyond the original disclosure of the application, as required by 37 CFR §1.825(a);

3. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Jan. 21, 2005  
date

Respectfully submitted,



Leon R. Yankwich; Reg. No. 30,237  
Michael R. Wesolowski; Reg. No.: 50,944  
Attorneys for Applicants  
Yankwich & Associates, P.C.  
201 Broadway  
Cambridge, MA 02139  
Telephone: (617) 374-3700  
Facsimile: (617) 374-0055